Hypera S.A. (HYPMY) Q2 2026 Earnings Call Transcript

Hypera S.A. ( HYPMY ) Q2 2026 Earnings Call August 7, 2026 10:00 AM EDT Company Participants Breno Pires de Oliveira - Chief Executive Officer Ramon Frutuoso Silva - CFO & Investor Relation Officer Conference Call Participants Joseph Giordano - JPMorgan Chase & Co, Research Division Antonio Cardoso - Jefferies LLC, Research Division Vinicius Figueiredo - Itaú Corretora de Valores S.A., Research Division Robert Ford - BofA Securities, Research Division Raphael Elage - Banco Bradesco BBI S.A., Research Division Artur do Amaral Alves - Morgan Stanley, Research Division Leandro Bastos - Citigroup Inc., Research Division Samuel Alves - Banco BTG Pactual S.A., Research Division Gustavo Miele - Goldman Sachs Group, Inc., Research Division Gustavo Tiseo - XP Investimentos Corretora de Câmbio, Títulos e Valores Mobiliários S.A., Research Division

Good morning, ladies and gentlemen. Welcome to Hypera Pharma's Earnings Call for the second quarter of 2026. We have with us Mr. Breno Oliveira, CEO; and Mr. Ramon Sanches, CFO and Investor Relations Officer. This event is being recorded and may be watched on the company's Investor Relations website at ri.hypera.com.br.

Before proceeding, we would like to remind you that some of the information contained in this conference call may include forward-looking statements or expectations about future events. This information is subject to known and unknown risks and uncertainties that may cause actual results to differ materially from those expressed or implied. I will now turn it over to Mr. Breno Oliveira, who will begin the company's presentation. Go ahead, sir.

Breno Pires de Oliveira Chief Executive Officer Good morning, everyone. It's a pleasure to welcome you to our earnings conference call for the second quarter of 2026. I'll begin the presentation on Slide 3. This quarter, we combined growth in sell-out, revenue, EBITDA and net income with strong operating cash flow and reduction in net debt. Our net revenue grew 8.5%, driven primarily by 7.6% growth in